Private Market Investment Banking
Full-spectrum investment banking services across mergers and acquisitions, private capital markets, structured financing, and corporate strategy — exclusively in private markets.
Scope Notice: Innekto Incorporated provides investment banking services exclusively in private markets. The firm does not offer, and has never offered, IPO advisory, public offering underwriting, or public market listing services of any kind.
Four Core Practice Areas
Mergers & Acquisitions
Buy-side and sell-side advisory mandates across sectors and geographies. From strategic assessment through transaction execution, we deliver independent, rigorous counsel to boards and shareholders.
Private Capital Markets
Capital raising mandates in private equity, growth capital, and venture financing. Sole placement agent and co-advisor capabilities across institutional LPs, family offices, and sovereign funds.
Structured & Bespoke Financing
Arrangement and structuring of bespoke financing solutions including commodity-backed facilities, real-asset lending, and cross-border structured credit for institutional and corporate clients.
Corporate Strategy & Advisory
Independent strategic advisory to boards and executive management on corporate transformation, strategic alternatives analysis, and complex transaction decisions.
Representative Completed Transactions
Exclusive financial advisor to a women's health pharmaceutical business on its divestiture to a strategic acquirer. Managed the full sell-side process from positioning through close.
Financial advisor to a specialty pharmaceutical company in a landmark $28 billion acquisition, one of the largest pharma transactions of the year. Provided strategic counsel across valuation, negotiation, and transaction execution.
Exclusive financial advisor to a radiosurgery company in its $277 million acquisition of a radiation therapy platform, expanding its oncology technology portfolio.
Financial advisor to a contract research organisation (CRO) on its sale to a strategic buyer. Supported the full divestiture process including buyer outreach, due diligence coordination, and definitive agreement.
Exclusive financial advisor to an acquirer in its $380 million buy-side mandate to acquire a developer of cystic fibrosis therapeutics, a high-priority rare disease asset.
Exclusive financial advisor to a specialty pharmaceutical company on its $150 million sale to a strategic acquirer. Conducted a competitive process resulting in a premium outcome for the seller.
Exclusive financial advisor to a home healthcare services provider on its $343 million sale, navigating a complex regulatory landscape and coordinating across multiple qualified strategic bidders.
Exclusive financial advisor to a specialty pharmaceutical company on its $637 million sale. Managed a broad process with institutional strategic buyers and coordinated regulatory clearance planning.
Exclusive financial advisor to an ophthalmic surgery products company on its $2.8 billion sale — a landmark transaction in the ophthalmic devices sector. Managed full process from pre-launch positioning to close.
Exclusive financial advisor to a cochlear implant manufacturer on its $489 million sale to a strategic acquirer, supporting a competitive process across global hearing technology buyers.
Exclusive financial advisor to an animal health company in the acquisition of veterinary products business units from a diversified life sciences group. Advised on strategic fit, structure, and transaction execution.
Joint bookrunning manager on a $21 billion multi-tranche bond issuance for a specialty pharmaceutical company, one of the largest pharmaceutical bond offerings of the year.
Joint lead arranger and bookrunner for a $5 billion permanent bank facility supporting a specialty pharmaceutical company's $66 billion strategic acquisition, providing bridge-to-permanent financing.
Joint lead arranger and bookrunner for a $7 billion bridge-to-bonds and loan facility structured to support a $28 billion pharmaceutical acquisition, coordinating across a large bank syndicate.
Lead arranger for a $14 billion bridge loan structured to support the acquisition of a major consumer health business, executed across a multi-lender syndicate with tight timeline requirements.
Joint lead arranger and bookrunner for a $6 billion term loan facility structured to fund the acquisition of an oncology company, coordinating regulatory approval conditions into the financing terms.
Lead arranger for a $1.07 billion leveraged loan supporting the private equity-backed acquisition of a pharmaceutical capsule manufacturer, structuring a financing package suited to the PE hold period.
Underwriter for a $300 million Senior Notes offering by a specialty chemicals company, providing long-term fixed-rate debt capital to support operational and strategic objectives.
Joint arranger for $7 billion of bridge, asset sale, and incremental credit facilities structured to support a major pharmaceutical merger, managing a complex multi-instrument financing across a broad syndicate.
Joint bookrunning manager on a concurrent $7.4 billion stock and convertible note offering by a specialty pharmaceutical company — one of the largest combined equity and convertible transactions in the sector.
Underwriter on a $433 million follow-on equity offering for an oncology biopharmaceutical company, supporting clinical pipeline advancement and commercialisation activities.
Underwriter on a $138 million follow-on equity offering for an epigenetics-focused oncology company, funding continued R&D across its cancer biology pipeline.
Underwriter on a $116 million follow-on equity offering for a synthetic biology company, providing growth capital to scale manufacturing and commercial operations.
Underwriter on a $110 million follow-on equity offering for a nephrology biopharmaceutical company focused on rare kidney diseases, funding late-stage clinical development.
Underwriter on an $87 million follow-on equity offering for an oncology biopharmaceutical company, supporting advancement of its targeted therapy pipeline through clinical milestones.
Exclusive placement agent for a private placement of equity in an aquatic biomass company, coordinating capital from a Middle Eastern institutional fund to support sustainable resource development.
Joint bookrunning manager on an $80 million follow-on equity offering for a biological testing and diagnostics company, funding expansion of its laboratory services platform.
Transaction Provenance Note: The transactions listed above are representative of mandates completed by Innekto Incorporated and mandates completed by senior members of the Innekto team over their careers at leading financial institutions prior to Innekto's formation. Debt and equity capital market transactions were executed as part of institutional banking mandates at predecessor institutions and are included to illustrate the senior team's depth of sector and transaction experience. All transactions are presented for illustrative purposes only. Client identities and confidential pricing details are not disclosed.
Typical Engagement Process
Scope, objectives, and timeline agreed. Engagement letter executed. Dedicated MD-level team appointed.
Financial modelling, valuation, positioning, and process materials prepared. Data room structured.
Qualified counterparties engaged. Management presentations conducted. Indications of interest received and evaluated.
Preferred party selected. Due diligence managed. Definitive documentation negotiated and transaction closed.
Sectors We Serve
Discuss a Transaction Mandate
Our banking team works with a limited number of clients at any given time, ensuring senior attention at every stage. Contact us to discuss your transaction requirements.
Request a MeetingThe information presented on this page is intended for institutional counterparties and professional investors only. All references to target returns, yield strategies, and projected outcomes represent forward-looking estimates subject to material market, credit, liquidity, and operational risks. Past performance is not indicative of future results. Nothing herein constitutes an offer to buy or sell securities or investment products.